Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 13 - Drugs for disorders of the urinary system
Patents for A61P 13 - Drugs for disorders of the urinary system (56,135)
09/2005
09/21/2005CN1671668A 4-(substituted aryl)-5-hydroxyisoquinolinone derivative
09/21/2005CN1671666A Vegfr-2 and vegfr-3 inhibitory anthranylamidopyridines
09/21/2005CN1671662A Piperidine derivative, process for producing the same, and use
09/21/2005CN1671424A Decoy composition for treating and preventing inflammatory disease
09/21/2005CN1671421A Inclusion complexes of rosiglitazone
09/21/2005CN1671390A Adenosine A2A receptor antagonists for treating restless legs syndrome or related disorders
09/21/2005CN1671379A Hydrazonopyrazole derivatives and their use as therapeutics
09/21/2005CN1671365A Improved transdermal delivery system
09/21/2005CN1219780C Heterocyclic compounds binding chemotactic factor receptor
09/21/2005CN1219763C Substituted indole mannich bases
09/21/2005CN1219545C Polygonum capitatum extract and medicinal composition preparation thereof
09/21/2005CN1219536C Lithiasis treating Chinese medicine preparation
09/21/2005CN1219530C Medicine with toxin expelling, gallbladder normalizing and liver protecting function
09/20/2005US6946491 such as 3-[(4-(2-fluorobenzyloxy)phenyl)-methylthio]propionic acid; for treatment of insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis
09/20/2005US6946484 Controlling cancer by reducing its growth and improving response to therapy
09/20/2005US6946471 2-(2,6-Dichlorophenyl)-Diarylimidazoles
09/20/2005US6946454 Thio-oxindole derivatives
09/20/2005US6946444 Modify the activity of the lipolysis stimulated receptor and can be used to influence the partitioning of dietary lipids between the liver and peripheral tissues; treating obesity-related insulin resistance
09/20/2005US6946244 Detecting the activity of orphan G Protein Receptor 86 by incubating a sample comprising GPR86 and adenosine diphosphate (ADP) under binding conditions for both and detecting a second messanger; screening for a modulator
09/20/2005CA2211668C Substituted heterocyclic compounds, preparation method therefor and pharmaceutical compositions containing the same
09/20/2005CA2170606C Type i angiotensin ii receptor specific monoclonal antibodies and hybridomas
09/15/2005WO2005085267A1 Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
09/15/2005WO2005085241A1 Thiazole derivative
09/15/2005WO2005085228A1 Cycloalkanopyridine derivative
09/15/2005WO2005085212A1 Substituted pyrimidine derivative
09/15/2005WO2005085210A1 Nitriles and medicinal compositions containing the same as the active ingredient
09/15/2005WO2005085200A1 Pyridone derivative
09/15/2005WO2005085195A1 Medicinal composition for prevention or treatment of overactive bladder accompanying nervous disorder
09/15/2005WO2005084709A1 Remedy for urinary disorder
09/15/2005WO2005084702A1 Agent for preventing and treating organ fibrosis
09/15/2005WO2005084679A1 Composition containing benzamidine derivative and method for stabilizing benzamidine derivative
09/15/2005US20050203189 2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline; inhibiting Na+/Ca2+ exchanger 1 (NCX1)
09/15/2005US20050203165 Perfectly reproducible crystalline form that especially exhibits valuable characteristics for formulation of inhibitors of angiotensin I converting enzyme; preparation from a solution of the salt in CH2Cl2 or ethyl acetate; treating cardiovascular disease
09/15/2005US20050203164 Administering (4R)-[N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(1-methyl-indol-3-yl)-pent-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide; constipation, diarrhoea, functional dyspepsia, gastro-oesophageal reflux disease, functional abdominal bloating
09/15/2005US20050203153 Drugs with carriers as prodrugs for anticancer agents
09/15/2005US20050203126 Inhibitors of basic fibroblast growth factors (FGFs); treating cancer, rheumatoid arthritis, inflammatory bowel disease, cardiovascular disorders, diabetic retinopathy, achondroplasia, hypochondoplasia, or thanathophoric dysplasia
09/15/2005US20050203114 Pyrimidine-indole derivatives; cancer, autoimmunological, metabolic, inflammatory, infection (bacterial, viral, yeast, fungal, etc.), diseases of the central nervous system, degenerative neural disease, allergy/asthma, dermatology, angiogenesis, neovascularization, vasculogenesis, and cardiovascular
09/15/2005US20050203113 Compounds and method for the treatment of overactive bladder
09/15/2005US20050203109 Novel Compounds
09/15/2005US20050203093 Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4
09/15/2005US20050203066 Preventing mitochondrial respiratory chain dysfunction in mammal by administering a pyrimidine nucleotide precursor and pyruvic acid, ester or salt; neurodegenerative, muscular, urogenital, or developmental disorders; autism, neuropathic pain, headaches; anticarcinogenic agents; cognition activators
09/15/2005US20050203065 Use of A2b adenosine receptor antagonists such as 3-[4-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[2.2.2]oct-1-yl]-propionic acid (BG 9928)
09/15/2005US20050203030 Novel effectors of dipeptidyl peptidase IV
09/15/2005US20050202412 Potentiators of serotonin reuptake inhibitors; cyclohexane carboxylic acid-((1r)-1-cyclohexylmethyl-2-(4-(2-methoxy phenyl)-piperazin-1-yl)ethyl)amide derivatives; for treatment of schizophrenia, paranoia and mano-depressive illness
09/15/2005US20050202018 Binding agent, conjugated to a keyhole limpet hemocyanin, that specifically binds to circulating prostate specific antigen and induces a therapeutic immune response
09/15/2005US20050202008 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
09/15/2005US20050201984 An adenoviral genome replaced with a therapeutic gene or DNA sequence regulated by a ubiquitous promoter either a Cytomegalo virus promotor or a tissue-specific phosphoenolpyruvate carboxykinase promoter, where gene or sequence encodes for a latent human metalloprotease gene MMP-8 (collengenases)
09/15/2005CA2558274A1 Cycloalkanopyridine derivative
09/15/2005CA2557766A1 Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
09/15/2005CA2557758A1 Medicinal composition for prevention or treatment of overactive bladder accompanying nervous disorder
09/14/2005EP1574575A1 GLUCOSE AND/OR FRUCTOSE TRANSPORTER NaGLT1 AND ITS GENE
09/14/2005EP1574219A2 Method of inhibiting fibrosis with a somatostatin agonist
09/14/2005EP1574218A1 A medicament containing epidemium extract for treatment of prostatic hyperplasia and prostatitis
09/14/2005EP1574215A1 Solid drug for oral use
09/14/2005EP1573031A2 Androgen regulated nucleic acid molecules and encoded proteins
09/14/2005EP1572995A2 Novel proteins and nucleic acids encoding same
09/14/2005EP1572892A2 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
09/14/2005EP1572881A2 Tacis and br3 polypeptides and uses thereof
09/14/2005EP1572877A2 Drug metabolizing enzymes
09/14/2005EP1572867A2 Endothelial cell expression patterns
09/14/2005EP1572863A2 Method for identifying inhibitors of g protein coupled receptor signaling
09/14/2005EP1572725A1 Novel chi-conotoxin peptides (-i)
09/14/2005EP1572659A2 The use of 4-phenyl substituted tetrahydroisoquinolines in the treatment of pain, migraine and urinary incontinence
09/14/2005EP1572658A1 The use of 4-phenyl-substituted tetrahydroisoquinolines in the treatment of pain, migraine headaches and urinary incontinence
09/14/2005EP1572641A1 Method for production of the r,r (or s,s) configuration of glycopyrronium stereoisomers
09/14/2005EP1572632A1 Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists
09/14/2005EP1572183A1 Alpha-2-delta ligand for the treatment of sexual dysfunction
09/14/2005EP1572181A2 Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor and the use of said composition for treating bladder dysfunction
09/14/2005EP1572173A1 Alpha-2-delta ligand to treat lower urinary tract symptoms
09/14/2005EP1572172A1 Alpha2delta ligands for different pharmaceutical uses
09/14/2005EP1572071A2 Systems and methods for treating patients with processed lipoaspirate cells
09/14/2005EP1392643B1 Trisubstituted-n- (1s)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit p2x3 and p2x2/3 containing receptors
09/14/2005EP1200402B1 Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain
09/14/2005EP1137422B1 Use of human prostate cell lines for the treatment of prostate cancer
09/14/2005CN1668728A A process for decreasing environmental pollutants in an oil or a fat, a volatile environmental pollutants decreasing working fluid, a health supplement, and an animal feed product
09/14/2005CN1668628A Novel thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof
09/14/2005CN1668619A Imidazo[1, 2-a]pyrazin-8-ylamines, method of making and method of use thereof
09/14/2005CN1668614A Bicyclic piperidine derivatives as antagonists of the CCR1 chemokine receptor
09/14/2005CN1668589A Indoline derivatives substituted in the 6 position, their preparation and their use as medicaments
09/14/2005CN1668588A Indole derivatives, method for preparing same and pharmaceutical compositions containing same
09/14/2005CN1668585A 3, 6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
09/14/2005CN1668332A Liquid formulations with a high concentration of human growth hormone (HGH) comprising glycine
09/14/2005CN1668310A Hormone replacement therapy using a combination of conjugated estrogens and trimegestone
09/14/2005CN1668299A Methods for using JNK inhibitors for treating or preventing disease-related wasting
09/14/2005CN1668289A Modafinil pharmaceutical compositions
09/14/2005CN1668285A Lasofoxifene tablet and its coating
09/14/2005CN1666774A Medicine for treating calculus and preparation process thereof
09/14/2005CN1666763A Dripping pills of six Ingredients with Rehmanniae
09/14/2005CN1218940C Nitric oxide synthase inhibitors
09/14/2005CN1218936C Carboxamide-substituted phenylurea derivatives, process for their preparation and their use as medicaments
09/14/2005CN1218739C Application of Chinese lizardtail herb and its extractive in preventing and treating prostatosis
09/14/2005CN1218716C Medicine for treating toxuria, and its prepn. method
09/14/2005CN1218709C Chinese medicine for treating uremia
09/13/2005US6943188 For manufacture of medicament for use in treating asthma, multiple sclerosis, inflammatory disease
09/13/2005US6943183 Antiproliferative agnets; anticancer agents; skin disorders; restenosis
09/13/2005US6943176 Heterocyclic derivatives
09/13/2005US6943171 For therapy of urological, vascular or pulmonary disorders
09/09/2005WO2005082889A1 Piperidinyl targeting compounds that selectively bind integrins
09/09/2005WO2005082887A1 Pyrimidine derivative
09/09/2005WO2005082865A1 Fused bicyclic pyrimidine derivative
1 ... 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 ... 562